1. Wang, H.-B. HIV vaccine research: The challenge and the way forward / H.-B. Wang, Q.-H. Mo, Z. J. Yang // J. Immunol. Res. - 2015. - Vol. 2015. - Article 503978. https://doi.org/10.1155/2015/503978
2. Kumari, G. Highly active antiretroviral therapy for treatment of HIV/AIDS patients: current status and future prospects and the Indian scenario / G. Kumari, R. K. Singh // HIV AIDS Rev. - 2012. - Vol. 11, N 1. - P. 5-14. https://doi.org/10.1016/j. hivar.2012.02.003
3. Corti, D. Broadly neutralizing antiviral antibodies / D. Corti, A. Lanzavecchia // Annu. Rev. Immunol. - 2013. -Vol. 31, N 1. - P. 705-742. https://doi.org/10.1146/annurev-immunol-032712-095916
4. Mann, J. K. HIV-1 vaccine immunogen design strategies / J. K. Mann, T. Ndung’u // Virol. J. - 2015. - Vol. 12, N 1. -P. 3. https://doi.org/10.1186/s12985-014-0221-0
5. Small-molecule HIV-1 entry inhibitors targeting gp120 and gp41: a patent review (2010-2015) / W. Li [et al.] // Expert Opin. Ther. Pat. - 2017. - Vol. 27, N 6. - P. 707-719. https://doi.org/10.1080/13543776.2017.1281249
6. Wilen, C. B. HIV: Cell binding and entry / C. B. Wilen, J. S. Tilton, R. W. Doms // Cold Spring Harb. Perspect. Med. -2012. - Vol. 2, N 8. - P. a006866. https://doi.org/10.1101/cshperspect.a006866
7. Computational methods in drug discovery / G. Sliwoski [et al.] // Pharmacol. Rev. - 2014. - Vol. 66, N 1. - P. 334-395. https://doi.org/10.1124/pr.112.007336
8. In silico дизайн и оценка потенциальной активности новых ингибиторов ВИЧ-1 - миметиков первичного рецептора CD4 белка gp120 оболочки вируса / А. М. Андрианов [и др.] // Докл. Нац. акад. наук Беларуси. - 2017. - Т. 61, № 3. - С. 47-57.
9. AMBER 11 / D. A. Case [et al.]. - San Francisco, Univ. California, 2010. - 296 p.
10. MMPBSA.py: An efficient program for end-state free energy calculations / B. R. Miller [et al.] // J. Chem. Theory Comput. - 2012. - Vol. 8, N 9. - P. 3314-3321. https://doi.org/10.1021/ct300418h
11. Structure-based design of a small molecule CD4-antagonist with broad spectrum anti-HIV-1 activity / F. Curreli [et al.] // J. Med. Chem. - 2015. - Vol. 58, N 17. - P. 6909-6927. https://doi.org/10.1021/acs.jmedchem.5b00709
12. Energetics of the HIV gp120-cD4 binding reaction / D. G. Myszka [et al.] // Proc. Natl. Acad. Sci. USA. - 2000. -Vol. 97, N 16. - P. 9026-9031. https://doi.org/10.1073/pnas.97.16.9026
13. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody / P. D. Kwong [et al.] // Nature. - 1998. - Vol. 393, N 6686. - P. 648-659. https://doi.org/10.1038/31405
14. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings / C. A. Lipinski [et al.] // Adv. Drug Deliv. Rev. - 2001. - Vol. 46, N 1-3. - P. 3-26. https://doi.org/10.1016/s0169-409x(00)00129-0
15. Brase S., Banert K. Organic Azides: Syntheses and applications. - Wiley, 2009. - 507 p. https://doi.org/10.1002/9780470682517
